Advertisement


Meletios A. Dimopoulos, MD, on Waldenström’s Macroglobulinemia

2018 ASCO Annual Meeting

Advertisement

Meletios A. Dimopoulos, MD, of the National and Kapodistrian University of Athens, discusses phase III findings on ibrutinib/rituximab vs placebo/rituximab in Waldenström’s macroglobulinemia (Abstract 8003).



Related Videos

Lymphoma
Immunotherapy

Nathan Hale Fowler, MD, and Julie M. Vose, MD, MBA, on Follicular Lymphoma: Results From the RELEVANCE Trial

Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, and Nathan Hale Fowler, MD, of The University of Texas MD Anderson Cancer Center, discuss phase III study findings on lenalidomide plus rituximab vs chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma (Abstract 7500).

Gynecologic Cancers
Immunotherapy

Ursula A. Matulonis, MD, and Stéphanie Gaillard, MD, PhD, on Ovarian Cancer: Results From an NRG Oncology/COG Trial

Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Stéphanie Gaillard, MD, PhD, of Duke Cancer Institute, discuss an evaluation of bevacizumab in the primary treatment of advanced ovarian cancer (Abstract 5517).

Breast Cancer

Michael Gnant, MD, on Breast Cancer: Results From the ABCSG-18 Trial

Michael Gnant, MD, of the Medical University of Vienna, discusses study findings on adjuvant denosumab in early breast cancer––a disease-free survival analysis of postmenopausal patients.

Geriatric Oncology

Supriya G. Mohile, MD, on Communicating With Older Cancer Patients: Results From a Community Trial

Supriya G. Mohile, MD, of the University of Rochester Medical Center, discusses study findings on ways to improve communication with older cancer patients using geriatric assessment (Abstract LBA10003).

Skin Cancer

Paolo A. Ascierto, MD, on Melanoma: Results From the COLUMBUS Trial

Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori–Fondazione Pascale, discusses phase III study findings on encorafenib plus binimetinib vs vemurafenib or encorafenib in BRAF-mutant melanoma (Abstract 9504).

Advertisement

Advertisement




Advertisement